0000000000558741
AUTHOR
Italiano E
Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: The PAUSE study
Abstract Background Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE). Its safety was established in a thorough clinical development program. Objective To characterize the safety profile of dapoxetine in PE treatment and to report the incidence, severity, and type of adverse events. Design, setting, and participants We conducted a 12-wk, open-label, observational study with a 4-wk, postobservational contact. A total of 10 028 patients were enrolled, with 6712 patients (67.6%) treated with dapoxetine 30–60mg (group A)and 3316 (32.4%) treated with alternative care/nondapoxetine (group B). …
Paradoxical arterial priapism: post-traumatic monolateral low penile perfusion and curvature associated to contro-lateral arterious-cavernous aceration and fistulization.
Poster for IX Congress of the European Society for Sexual Medicine. Vienna, Dicember 3th – 6th 2006